All Premium Intelligence
Every PAULA briefing — newest first. Each ships with four critical questions answered and role-specific lenses available.
Payment Pathways for Clinical AI: Why Groundbreaking Tools Stall at the Billing Department
Six payment pathways every clinical AI leader must understand — CMS reimbursement, SaaS procurement, value-based care alignment — and the physician-led recommendations that move AI from pilot purgatory to payout.
Payer Prior-Auth APIs Go Live — Decision Rationale Becomes Discoverable
MA, Medicaid, CHIP, and FFM QHPs must run a PA API, return specific denial rationale, and meet 72hr/7d response windows. The rationale field becomes the appeal anchor. Revenue at risk: $780K–$1.7M.
MA Plans Must Now Justify Their UM Criteria — And You Can Demand to See Them
CY2026 MA Final Rule requires UM Committee review, public posting of internal criteria, and annual health-equity analysis of prior auth. Three new documentary demands per appeal. Revenue at risk: $920K–$1.9M.
EHR-Embedded Predictive AI Now Carries Source-Attribute Disclosure Obligations
Every predictive DSI in a certified EHR carries source-attribute and intervention risk management obligations — discoverable in payer disputes, OCR §1557, and state AG inquiries. Revenue at risk: $410K–$980K.
California's AI-in-UM Model Is Spreading — Texas and New York Are Next
TX and NY are advancing physician-final-decision bills patterned on CA SB 1120. One appeal frame scales across emerging statutes. Revenue at risk: $640K–$1.4M.
New State AI-in-UM Law Reshapes Payer Obligations in Your Market
California SB 1120 (Physicians Make Decisions Act) prohibits AI-only medical necessity denials by Knox-Keene plans and disability insurers. Licensed physician must make the final call, based on individualized clinical circumstances. Revenue at risk: $542K–$1.1M.
New AI Service Pathway Creates Reimbursement Opportunity — and Audit Exposure
FY 2027 IPPS Proposed Rule (CMS-1849-P) would repeal the alternative NTAP pathway for FDA Breakthrough Device-designated AI products beginning FY 2028. All AI devices would need to meet the full three-criteria standard. Revenue at risk: $643K–$1.3M.
AI-Driven Denials Now Require Defensible Human-Review Documentation
CMS-4201-F prohibits MA plans from using algorithms as the sole basis for adverse coverage decisions. ONC HTI-1 and HHS OCR §1557 expand the legal exposure of unaudited AI in UM. Every AI-assisted denial requires contemporaneous human-review attestation.
CMS IPO Change Creates Immediate Admission Denial Risk
CY 2026 OPPS final rule phases out 285 procedures from the Inpatient-Only list, resetting site-of-service denial logic. Two-Midnight documentation becomes the controlling defense for every Table 119 admission.
Federal Enforcement Signals Expanding Payer-Behavior Scrutiny
Senate PSI 'Refusal of Recovery' report documents UHC, Humana, and CVS/Aetna MA post-acute denial patterns tied to nH Predict and Post-Acute Analytics. CLIP-grade appeal record-building required for every AI-assisted denial.
Two-Midnight Enforcement Will Drive Observation Downgrades
MAC TPE has replaced BFCC-QIO review for short-stay inpatient admissions. PA, CFO, and Compliance lenses with denial scenarios and PIM Exhibit 48 citations.
WISeR Prior Auth Tightening Across Traditional Medicare
CMS's WISeR pilot extends AI-assisted prior authorization into Traditional Medicare for targeted services. UM, denial-risk, and documentation framing for affected service lines.